Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.34 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.33 |
| ▸ | PLAU | P00749 | 2/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17492936 | 1.00 | FPR2 (0.34) | FPR2F10ACACBITGA4ITGB7 | |
| SCHEMBL17468557 | 0.94 | FPR2 (0.34) | FPR2ACACBITGA4ITGB7ITGB1 | |
| SCHEMBL28532158 | 0.94 | F10 (0.39) | FPR2F10ACACBPLAUPLG | |
| SCHEMBL17945643 | 0.94 | F10 (0.39) | FPR2F10ACACBPLAUPLG | |
| SCHEMBL28532160 | 0.94 | F10 (0.39) | FPR2F10ACACBPLAUPLG | |
| SCHEMBL16306070 | 0.94 | F10 (0.39) | FPR2F10ACACBPLAUPLG | |
| SCHEMBL16305977 | 0.94 | ACACB (0.35) | FPR2ACACBPRCP | |
| SCHEMBL22384298 | 0.94 | ACACB (0.35) | FPR2ACACBPRCP | |
| SCHEMBL16343488 | 0.92 | PYGL (0.38) | FPR2ACACBITGA4ITGB7ITGB1 | |
| SCHEMBL16295882 | 0.92 | PYGL (0.38) | FPR2ACACBITGA4ITGB7ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519407-B1 | DIMETHYLAMINOETHANOL SALT OF A GLP-1 RECEPTOR MODULATOR | RECEPTOS LLC (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3519407-B1 | DIMETHYLAMINOETHANOL SALT OF A GLP-1 RECEPTOR MODULATOR | RECEPTOS LLC (US) | 2021-09-22 | — | — | EP | disclosed |
| US-11066395-B2 | Dimethylaminoethanol salt of a GLP-1 receptor modulator | RECEPTOS LLC (US) | 2021-07-20 | — | — | US | disclosed |
| CN-107074820-B | GLP-1 receptor modulators | 赛尔基因第二国际有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112457301-A | Novel GLP-1 receptor modulators | 赛尔基因第二国际有限公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-20200131164-A1 | DIMETHYLAMINOETHANOL SALT OF A GLP-1 RECEPTOR MODULATOR | RECEPTOS LLC | 2020-04-30 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| WO-2016015014-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | FPR2 492/4885F10 1321/4885ACACB 3909/4885 |
| US-20200131164-A1 | DIMETHYLAMINOETHANOL SALT OF A GLP-1 RECEPTOR MODULATOR | GLP1R, GIPR, GPR119 | FPR2 845/4885F10 4477/4885ACACB 3343/4885 |
| US-11066395-B2 | Dimethylaminoethanol salt of a GLP-1 receptor modulator | GLP1R, GIPR, GPR119 | FPR2 845/4885F10 4477/4885ACACB 3343/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | FPR2 499/4885F10 1183/4885ACACB 3721/4885 |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | FPR2 740/4885F10 1798/4885ACACB 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.